Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases [4] - The company aims to provide "off-the-shelf" CAR T cell product candidates that are readily available, reliable, and scalable for patient treatment [4] Upcoming Events - Allogene Therapeutics will report its second quarter 2025 financial results and provide a business update on August 13, 2025, after market close [1] - A live audio webcast and conference call will follow the announcement at 2:00 p.m. PT/5:00 p.m. ET [1] Webcast Information - The listen-only webcast will be available on the company's website under the Investors tab in the News and Events section, with a replay accessible for approximately 30 days [2] - Registration is required for those who wish to ask questions during the conference call, and participants will receive a personal PIN upon registration [3]